FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for ARANESP (darbepoetin alfa) submitted by Amgen, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia Due to Chronic Kidney Disease
• Chemotherapy-induced Anemia

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

SUPPL AP for ARANESP (DARBEPOETIN ALFA)